Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Curr Osteoporos Rep ; 21(4): 330-343, 2023 08.
Article in English | MEDLINE | ID: mdl-37329384

ABSTRACT

PURPOSE OF REVIEW: This article gives a brief overview of the most recent developments in osteosarcoma treatment, including targeting of signaling pathways, immune checkpoint inhibitors, drug delivery strategies as single or combined approaches, and the identification of new therapeutic targets to face this highly heterogeneous disease. RECENT FINDINGS: Osteosarcoma is one of the most common primary malignant bone tumors in children and young adults, with a high risk of bone and lung metastases and a 5-year survival rate around 70% in the absence of metastases and 30% if metastases are detected at the time of diagnosis. Despite the novel advances in neoadjuvant chemotherapy, the effective treatment for osteosarcoma has not improved in the last 4 decades. The emergence of immunotherapy has transformed the paradigm of treatment, focusing therapeutic strategies on the potential of immune checkpoint inhibitors. However, the most recent clinical trials show a slight improvement over the conventional polychemotherapy scheme. The tumor microenvironment plays a crucial role in the pathogenesis of osteosarcoma by controlling the tumor growth, the metastatic process and the drug resistance and paved the way of new therapeutic options that must be validated by accurate pre-clinical studies and clinical trials.


Subject(s)
Bone Neoplasms , Lung Neoplasms , Osteosarcoma , Child , Young Adult , Humans , Immune Checkpoint Inhibitors/pharmacology , Immune Checkpoint Inhibitors/therapeutic use , Osteosarcoma/drug therapy , Lung Neoplasms/drug therapy , Lung Neoplasms/secondary , Bone and Bones/pathology , Bone Neoplasms/drug therapy , Tumor Microenvironment
2.
J Cell Physiol ; 233(8): 5696-5715, 2018 08.
Article in English | MEDLINE | ID: mdl-29323712

ABSTRACT

Bisphosphonates are considered the most effective drugs for controlling adult and pediatric osteolytic diseases. Although they have been used successfully for many years, several side effects, such as osteonecrosis of the jaw, delayed dental eruption, atypical femoral fracture, and alterations to the bone growth system, have been described. After an overview of nitrogenous bisphosphonate, the purpose of this article is to describe their mechanisms of action and current applications, review the preclinical and clinical evidence of their side effects in the skeleton ("what we know"), and describe current recommendations for preventing and managing these effects ("what we can do"). Finally, promising future directions on how to limit the occurrence of these side effects will be presented.


Subject(s)
Bone Density Conservation Agents/adverse effects , Diphosphonates/adverse effects , Skeleton/drug effects , Animals , Humans , Osteonecrosis/chemically induced
SELECTION OF CITATIONS
SEARCH DETAIL
...